Learn more about our current news, views and updates
For any media enquiries please contact Natalie Samuel: contact@micreos.com
07/03/2023
Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression.
Read More01/03/2023
Since its founding in 2005, Micreos has become a world leading developer of endolysin and phage technology, enabling the targeted killing of only unwanted bacteria while protecting the rest of the Microbiome.
Read More25/10/2022
Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.
Read More18/10/2022
Dr. Matthew Dunne, Dr. Samuel Kilcher and Dr. Anja Keller join us from the Swiss Federal Institute of Technology (ETH Zurich), with the goal of developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.
Read More14/04/2022
Zug, Switzerland, 14 April 2022 — Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR).
Read More05/04/2022
Zug, Switzerland, 5-April 2022 — Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer.
Read More14/10/2021
The Hague, October 14, 2021 - Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland.
Read More30/09/2021
THE HAGUE, The Netherlands, 30 September, 2021 - Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria.
Read More22/09/2020
The Hague, 22 September 2020, Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.
Read More